

Advocacy services for adults with health and social care needs

NICE guideline: methods

NICE guideline TBC

Supplement 1: Methods

June 2022

Draft for Consultation

Evidence reviews were developed by the National Guideline Alliance hosted by the Royal College of Obstetricians and Gynaecologists

Disclaimer

The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.

Local commissioners and/or providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.

NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the [Welsh Government](#), [Scottish Government](#), and [Northern Ireland Executive](#). All NICE guidance is subject to regular review and may be updated or withdrawn.

Copyright

© NICE 2022. All rights reserved. Subject to [Notice of Rights](#).

ISBN:

Contents

Development of the guideline	5
Remit.....	5
What this guideline covers.....	5
What this guideline does not cover.....	6
Methods	7
Identifying recommendations from existing NICE guidelines.....	7
Searching for existing recommendations on advocacy.....	7
Extraction of recommendations and thematic analysis.....	8
Call for evidence.....	8
Additional evidence identified by the guideline committee.....	8
Inclusion/exclusion criteria.....	9
Appraising the quality of evidence.....	9
Existing NICE guidelines.....	9
Call for evidence and evidence identified by the guideline committee.....	10
Formal consensus.....	13
Details of the nominal group technique as used in this guideline.....	13
Reviewing economic evidence.....	14
Appraising the quality of economic evidence.....	14
Economic modelling.....	15
Cost effectiveness criteria.....	15
Other sources of evidence.....	16
External experts (expert witness).....	16
Developing recommendations.....	16
Adopting and adapting existing NICE recommendations.....	17
New guideline recommendations based on formal consensus.....	17
New guideline recommendations based on informal consensus.....	18
Research recommendations.....	18
Validation process.....	18
Updating the guideline.....	Error! Bookmark not defined.
Funding.....	18
References	19

1 Development of the guideline

2 Remit

3 The National Institute for Health and Care Excellence (NICE) commissioned the
4 National Guideline Alliance (NGA) to develop a new social care guideline on
5 advocacy services for adults with health and social care needs.

6 What this guideline covers

7 Population

8 People with health and social care needs in all adult settings, including
9

- 10 • Those who have a legal right to an advocate
- 11 • Those who fund their own social care
- 12 • Young people under 18 who are accessing adult services

12 Key themes

- 13 • Identifying those who would benefit from advocacy
 - 14 ○ Who has a legal right to advocacy?
 - 15 ○ Who else would benefit from advocacy and how do we identify them?
- 16 • Facilitating advocacy
 - 17 ○ Improving access to advocacy (including addressing barriers)
 - 18 ○ Enabling and supporting effective advocacy (for example: time, approach,
19 environment, including virtual and non-face-to-face services)
 - 20 ○ Information about effective advocacy and signposting to services
 - 21 ○ Monitoring services and collecting data for quality improvement
 - 22 ○ Planning and commissioning services for advocacy (including for those who do
23 not have a legal right to advocacy)
 - 24 ○ Training and skills for practitioners who work with advocates
- 25 • Delivering advocacy
 - 26 ○ What does effective advocacy look like?
 - 27 ○ Partnership working and relationships with families and carers, commissioners
28 and providers
 - 29 ○ Training, skills and support for advocates

30 The evidence reviews corresponding to each area of the key themes in the scope are
31 summarised below.

32 **Table 1: Index to evidence reviews**

Evidence review	Scope area
[A] Who has a legal right to advocacy?	Who has a legal right to advocacy
[B] Who else would benefit from advocacy and how do we identify them?	Who would benefit from advocacy and how do we identify them?

Evidence review	Scope area
[C] Information about effective advocacy and signposting to services	Information about effective advocacy and signposting to services
[D] Improving access to advocacy	Improving access to advocacy (including addressing barriers)
[E] Enabling and supporting effective advocacy	Enabling and supporting effective advocacy (for example: time, approach, environment, including virtual and non-face-to-face services)
[F] What does effective advocacy look like?	What does effective advocacy look like?
[G] Partnership working and relationships with families and carers, commissioners and providers	Partnership working and relationships with families and carers, commissioners and providers
[H] Planning and commissioning services for advocacy	Planning and commissioning services for advocacy (including for those who do not have a legal right to advocacy)
[I] Training, skills and support for advocates	Training, skills and support for advocates
[J] Training and skills for practitioners who work with advocates	Training and skills for practitioners who work with advocates
[K] Monitoring services and collecting data for quality improvement	Monitoring services and collecting data for quality improvement

1 What this guideline does not cover

- 2 • Training courses to help people to advocate for themselves without third party
- 3 support
- 4 • Deciding when to provide non-instructed advocacy (although the guideline will
- 5 cover the provision of this service)
- 6 • Employment support advocacy
- 7 • Policy-based advocacy (including lobbying)
- 8 • Funding arrangements
- 9 • Legal decisions regarding mental capacity and mental health including assessing
- 10 capacity

1 **Methods**

2 It was not anticipated that evidence reviews would identify significant new research
3 on advocacy beyond that which has been identified in previous NICE guidelines (for
4 example, [the NICE guideline on decision-making and mental capacity](#)). Therefore,
5 new evidence reviews were not conducted for this guideline.

6 Recommendations on advocacy were identified from existing NICE guidelines and a
7 call for evidence was issued to identify any key sources that may have been omitted
8 from existing NICE guidelines. Statements relating to the key themes in the scope
9 were drawn from the documents received and formal consensus methods were used
10 to vote on these.

11 Recommendations were based on the statements, recommendations from existing
12 NICE guidelines and the knowledge and experience of the guideline committee (see
13 'Developing recommendations' below).

14 Declarations of interest were recorded according to the NICE conflicts of interest
15 policy.

16 **Identifying recommendations from existing NICE** 17 **guidelines**

18 **Searching for existing recommendations on advocacy**

19 A targeted keyword search of existing published NICE recommendations was
20 conducted to identify advocacy recommendations in existing NICE guidance.

21 The NGA team provided the following list of keywords to the NICE team to conduct
22 the search:

- 23 • advoca*
- 24 • self-advocacy
- 25 • voice
- 26 • “independent support” or “independent-support”
- 27 • “third party support” or “third-party-support”
- 28 • intermediary
- 29 • champion
- 30 • empower*
- 31 • “mentor support” or “mentor-support”
- 32 • “peer support” or “peer-support”
- 33 • “crisis intervention“ or “crisis-intervention“
- 34 • lobby or lobbying

35 An initial search was conducted in March 2020. A top-up search was conducted in
36 March 2021 to identify additional recommendations from guidelines published since
37 the initial search. The following, more focused, list of keywords was used for this
38 search:

- 1 • advoca*
- 2 • voice
- 3 • intermediary
- 4 • champion
- 5 • empower*

6 **Extraction of recommendations and thematic analysis**

7 The identified recommendations were added to Microsoft Excel, along with a record
8 of the guideline title and identifier and the year of publication.

9 Identified recommendations were screened and recommendations that did not
10 mention advocacy were excluded.

11 Recommendations that mentioned advocacy were reviewed and either categorised
12 into the pre-specified themes stated in the scope for this guideline or excluded if the
13 concepts covered by the recommendations were not relevant to any of the key
14 themes. Existing recommendations identified for each area of the scope are
15 presented in appendix F of the relevant evidence report.

16 **Call for evidence**

17 A targeted call for evidence was conducted to identify any key sources that may have
18 been omitted from existing NICE guidelines. This was issued directly to registered
19 stakeholders and via the NICE website. The call for evidence lasted for 2 weeks.

20 The call for evidence asked for evidence or guidelines published since 2005, or
21 unpublished information relating to research conducted since 2005, that covered:

- 22 • What effective advocacy looks like
- 23 • How to improve access to advocacy services
- 24 • Information and signposting to advocacy services
- 25 • Planning, commissioning and monitoring of advocacy services
- 26 • Advocacy services working with families and carers
- 27 • Training and skills for advocates

28 The following material was not considered as part of the call for evidence:

- 29 • promotional material
- 30 • unsubstantiated or non-evidence-based assertions of effectiveness
- 31 • opinion pieces or editorial reviews
- 32 • potentially unlawful or other inappropriate information

33 **Additional evidence identified by the guideline committee**

34 Following the call for evidence, the committee were presented with a summary of the
35 responses received and asked to identify any further evidence they were aware of
36 that was within the above parameters.

1 Inclusion/exclusion criteria

2 Inclusion and exclusion of documents received in response to the call for evidence or
3 from the guideline committee was based on the following criteria:

4 *Inclusion criteria*

- 5 • UK-based
- 6 • National focus. For guidelines and policy documents this was interpreted as the
7 policies/guidance applying nationally. For systematic reviews and primary
8 research this was interpreted as studies having been conducted in the national
9 context of the scope for this guideline (the English health and social care system)
- 10 • Conducted within the last 10 years (Note. a narrower date range was used than
11 specified in the call for evidence due to the volume of documents received).

12 *Exclusion criteria*

- 13 • Publication not based on evidence
- 14 • Publication based on non-systematic review or case-studies
- 15 • No key findings or recommendations reported that were relevant to the key
16 themes in the scope

17 A list of excluded documents for each area of the scope, including reasons for
18 exclusion is presented in Appendix D of the corresponding evidence review.

19 Appraising the quality of evidence

20 Existing NICE guidelines

21 The quality of evidence underpinning recommendations from existing NICE
22 guidelines was assessed as part of the development of the original guidelines, as
23 outlined in their methods sections. However, as the quality of evidence is in part
24 context-dependent, the overall quality of the guidelines was assessed for the purpose
25 of this guideline using the second version of the Appraisal of Guidelines of Research
26 and Evaluation (AGREE II) instrument (Brouwers 2010). Where guidelines have been
27 updated, quality assessment was based on the information available for the version
28 of the guideline that corresponded to the version that the relevant recommendation
29 was identified from. Further, when developing recommendations (see 'Developing
30 recommendations' below), the committee considered the original context for the
31 recommendation and how this could be generalised to a new context.

32 AGREE II is intended for assessing the quality of systematically developed clinical
33 practice guidelines, including assessments of methodological rigour and
34 transparency. The tool assesses 6 domains (see Table 1): scope and purpose,
35 stakeholder involvement, rigour of development, clarity of presentation, applicability
36 and editorial independence. Within each domain there is a set of questions, each of
37 which is scored using a 7-point scale (1 – 'strongly disagree' to 7 – 'strongly agree').
38 Each section is rated and then a score for each domain, as well as an overall rating,
39 is calculated (see the AGREE II for detailed instructions).

1 **Table 2: AGREE II domains**

Domain	Description
Scope and purpose	Assesses the aim of the guideline, the specific health questions, and the target population
Stakeholder involvement	Assesses the extent to which the guideline involved the appropriate stakeholders, and whether it represents the views of intended users
Rigour of development	Assesses the methods used to gather and synthesise the evidence and to construct the recommendations
Clarity of presentation	Assesses the language, format and structure of the guideline
Applicability	Assesses likely barriers and facilitators of implementation, uptake and resource implications of the guideline
Editorial independence	Assesses the likelihood of the recommendations being biased and potential conflict of interests

2 **Call for evidence and evidence identified by the guideline committee**3 ***Assessing methodological limitations in guidelines***

4 Methodological limitations in guidelines from the call for evidence or identified by the
5 guideline committee were also assessed using AGREE II. As described above,
6 AGREE II is intended for assessing the quality of clinical practice guidelines;
7 however, the documents included were broader than clinical practice guidelines, for
8 example guidelines from government and social care organisations and, therefore,
9 they were not developed to meet the standards set by AGREE II. Despite this,
10 AGREE II was considered to be the best available tool for use in the context of NICE
11 guideline development to support a systematic appraisal of the way in which the
12 included guidance documents were developed.

13 ***Assessing methodological limitations in systematic reviews***

14 Methodological limitations in systematic reviews were assessed using the Risk of
15 Bias in Systematic Reviews (ROBIS) tool (Whiting, 2016; see [appendix H in](#)
16 [Developing NICE guidelines: the manual](#)). The tool assesses concerns with the
17 review process in 4 domains (see Table 2): study eligibility criteria, identification and
18 selection of studies, data collection and study appraisal, and synthesis and findings.
19 Within each domain there is a set of signalling questions, each of which is answered
20 with yes, probably yes, probably no, no, or no information. The level of concern about
21 each domain is then summarised with low, high or unclear concerns, before an
22 overall rating of risk of bias in the review, which is either low, high or unclear.. The
23 overall rating of risk of bias in the review was not considered to purely be a 'count' of
24 the individual domain ratings, therefore no strict cut-offs were used to equate a
25 certain level or number of domain ratings with a particular overall assessment.
26 Judgements about the overall risk of bias in reviews were also influenced by
27 considerations about the extent to which the domain concerns were acknowledged
28 by authors and would be likely to undermine confidence in the review findings.

1 **Table 3: ROBIS domains**

Domain	Description
Study eligibility criteria	This domain assesses whether eligibility criteria were clear and appropriate and whether there was evidence that objectives and eligibility criteria were pre-specified
Identification and selection of studies	This domain assesses whether methods of study identification and selection were appropriate and whether efforts were made to minimise errors in selection
Data collection and study appraisal	This domain assesses whether data was extracted from studies appropriately, if appropriate tools were used to assess methodological quality and whether efforts were made to minimise errors in data collection and study appraisal
Synthesis and findings	This domain assesses whether data synthesis was appropriate and followed a pre-specified plan and whether the findings were robust

2 ROBIS is intended for assessing the quality of systematic reviews. However, the
3 documents assessed using this tool included reviews that were not intended by the
4 authors to be systematic. Therefore, they were not developed to meet the standards
5 of systematic reviews assessed by ROBIS. Despite this, ROBIS was considered to
6 be the best available tool for use in the context of NICE guideline development to
7 support a systematic appraisal of the way in which the included review documents
8 were developed.

9 ***Assessing methodological limitations in qualitative studies***

10 Methodological limitations in qualitative studies were assessed using the Critical
11 Appraisal Skills Programme (CASP) checklist (CASP Programme 2018) for
12 qualitative studies (see appendix H in Developing NICE guidelines: the manual).
13 Data from the qualitative studies were used to inform statements rather than to
14 underpin a thematic synthesis and development of review findings, so GRADE-
15 CERQual methodology could not be applied. This is because GRADE-CERQual is
16 intended for use assessing the confidence of evidence from reviews of qualitative
17 research rather than the quality of an individual study or study findings.

18 The CASP tool assesses methodological limitations across 10 areas (see Table 3):
19 aims of the research, appropriateness of using qualitative methodology, research
20 design, recruitment strategy, data collection, relationship between researcher and
21 participants, ethical considerations, data analysis, findings, and value of research.

22 **Table 4: CASP qualitative checklist domains**

Domain	Description
Aims of the research	This domain assesses whether the aims, importance and relevance of the study were described clearly
Appropriateness of using qualitative methodology	This domain assesses whether qualitative research methods were appropriate for investigating the research question, for example, does the study aim to interpret or illuminate actions or subjective experiences
Research design	This domain assesses whether the study approach has been documented clearly and

Domain	Description
	if it was justified, for example, based on a theoretical framework
Recruitment strategy	This domain assesses the procedure and reasons for the method of selecting participants and whether reasons for non-participation are discussed
Data collection	This domain assesses the documentation and justification of the method of data collection (in-depth interviews, semi-structured interviews, focus groups or observations). It also assesses where interviews took place, what form the data took (e.g., tape recordings, written notes) and data saturation
Relationship between researcher and participants	This domain assesses who conducted any interviews, any potential biases they might have and how these might have influenced the research questions or data collection. The assessment should include consideration of how the researcher responded to events during the study
Ethical considerations	This domain assesses whether ethical approval was obtained and ethical standards maintained, including issues of informed consent, confidentiality and the effect of the study on participants
Data analysis	This domain assesses whether sufficient detail was documented for the analytical process and whether it was in accordance with the theoretical approach. For example, if a thematic analysis was used, the assessment would focus on the description of the approach used to generate themes. Consideration of whether contradictory data are taken into account and whether the researcher considered their own biases during analysis and selection of data for presentation also forms part of this assessment
Findings	This domain assesses whether findings are credible, reported explicitly and discussed in the context of the original research question. It also assesses if findings for and against the researchers' arguments are discussed
Value of research	This domain assesses if the researchers discuss the generalisability of findings, the contribution they make to existing knowledge and directions for future research

1 Formal consensus

2 Formal consensus was used to agree statements that were used to inform
3 recommendations (see 'New guideline recommendations based on formal
4 consensus' below for more information). Formal consensus was carried out using the
5 nominal group technique (Murphy 1998). This is a structured method focusing on the
6 opinions of individuals within a group. Due to this focus on individuals, it is referred to
7 as a 'nominal group' technique. It usually involves anonymous voting with an
8 opportunity to provide comments and follows an iterative process in which options
9 with low agreement are eliminated and options with high agreement are retained.
10 Using the comments that individuals provided, options with medium agreement are
11 revised and then considered in a second round of voting.

12 Details of the nominal group technique as used in this guideline

13 Responses to the call for evidence and additional evidence identified by the guideline
14 committee provided the source material for the formal consensus process. The NGA
15 technical team assessed each document against the inclusion and exclusion criteria
16 (see 'Inclusion/exclusion criteria' above) and the relevant quality appraisal tool (see
17 'Appraising the quality of evidence' above). Relevant findings and recommendations
18 were then extracted for each of the key themes specified in the scope. These
19 findings and recommendations were then turned into statements for use in the formal
20 consensus process. Statements were edited to collate concepts reported from
21 multiple sources and to ensure each statement addressed a single, discrete issue but
22 otherwise reflected information as presented in the source material

23 The formal consensus exercise was conducted over email. Statements were sent to
24 the committee in a questionnaire format. All committee members were invited to take
25 part in the formal consensus exercise, excluding the chair and a minimum response
26 rate of 60% of committee members was required. Committee members were asked
27 to rate each statement based on their personal opinion of what they believed 'best
28 practice' would be. The statements were rated using a 9-point Likert scale, where 1
29 represents 'strongly disagree', 5 represents 'neither agree nor disagree', and 9
30 represents 'strongly agree'; 7 was the threshold for agreement with a statement.
31 Instead of rating the statement, participants could also record, with an 'X', if they
32 believed they had insufficient knowledge to provide a rating. A further alternative
33 response option was 'C', which indicated that the committee member felt they had a
34 conflict of interest stemming from their involvement in or authorship of documents
35 that were used to generate that statement. This meant that the number of people
36 providing an actual rating (1-9) could potentially vary for each statement depending
37 on people's perceived level of relevant knowledge or perceived conflict of interests.
38 Where people did not rate a statement due to a conflict of interest they nevertheless
39 participated in the meeting where the results of the voting and related
40 recommendations were discussed so that they could respond to questions from other
41 members of the committee, for example in relation to the documents on which
42 statements were based (see the [register of interests](#) for more information). Finally the
43 committee was also given the opportunity to provide written comments about each
44 statement regarding suggestions for revision or need for clarification.

45 Once this first round of consensus had been conducted, the NGA technical team
46 calculated overall percentage agreement for each individual statement and presented
47 the results to the committee. Statements with 80% or greater agreement were

1 retained and carried forward to committee discussions (see 'Developing
2 recommendations' below). Statements with 60% to 80% agreement were redrafted
3 by the NGA technical team (taking into account comments from the committee)
4 unless there were minor addressable issues that could be dealt with when
5 developing recommendations, in which case the statement was carried forward to
6 committee discussions. Where this happened, it is indicated in appendix G of the
7 individual reviews. Those with less than 60% agreement were discarded unless there
8 were obvious and addressable issues identified from any comments or raised by
9 members of the committee during presentation of the results, in which case the
10 statement was redrafted. Clarification on written comments and additional information
11 from the committee was sought by the NGA technical team, as needed, to inform the
12 redrafting of statements.

13 Redrafted statements underwent a second round of rating using the same process as
14 described above. Following the second round of rating, all statements were either
15 carried forward to committee discussions (using the same criteria as for round 1) or
16 discarded. No further redrafting of statements was undertaken.

17 When the formal consensus process started, there were 12 committee members
18 appointed. Therefore, there were 12 committee members eligible for voting for round
19 1 the below scope areas (which were the first to go through this process):

- 20 • Who has a legal right to advocacy?
- 21 • Who else would benefit from advocacy and how do we identify them?
- 22 • Training and skills for practitioners who work with advocates

23 An additional committee member was appointed between the first and second round
24 of voting for the above areas; therefore 13 committee members were eligible for
25 voting during round 2. For all remaining scope areas, there were 13 committee
26 members eligible for voting in both round 1 and round 2 as the additional committee
27 member was appointed before any rating of the statements occurred.

28 **Reviewing economic evidence**

29 It was not anticipated that the call for evidence would identify economic evidence
30 beyond that which has been identified in previous NICE guidelines. Therefore,
31 economic evidence reviews were not conducted for this guideline. Economic
32 evidence from the call for evidence would have been considered if it was within the
33 scope of the guideline.

34 **Appraising the quality of economic evidence**

35 No formal appraisal of economic evidence was undertaken but where economic
36 evidence was identified this was presented to the committee by an economist. Whilst
37 formal appraisal was not undertaken, the conclusions of the evidence were
38 presented and discussed with consideration of the economic evaluations checklist
39 specified in Developing NICE guidelines: the manual. Where identified economic
40 evidence was considered by the committee this was recorded in 'The committee's
41 discussion of the evidence'.

1 Economic modelling

2 The aims of the economic input to the guideline were to inform the guideline
3 committee of potential economic issues to ensure that recommendations represented
4 a cost effective use of healthcare resources. Economic evaluations aim to integrate
5 data on healthcare benefits (ideally in terms of quality-adjusted life-years; QALYs)
6 with the costs of different options. In addition, the economic input aimed to identify
7 areas of high resource impact; these are recommendations which (while cost
8 effective) might have a large impact on NHS, local authority or Third Sector finances
9 and so need special attention.

10 The guideline committee highlighted recommendations where implementation could
11 lead to a significant resource impact. These recommendations were considered for
12 economic modelling where such work was feasible and could potentially lead to
13 adaptation or reinforcement of the recommendation.

14 The following recommendations or broad areas covering multiple recommendations
15 were prioritised for economic modelling by the committee:

- 16 • Training for advocates

17

18 The methods and results of the de novo economic analyses are reported in Appendix
19 H of the relevant evidence report. When economic analysis was not prioritised, the
20 committee made a qualitative judgement regarding cost effectiveness by considering
21 expected differences in resource use and costs between options, alongside
22 effectiveness evidence.

23 Cost effectiveness criteria

24 NICE's report [Social value judgements: principles for the development of NICE](#)
25 [guidance](#) sets out the principles that committees should consider when judging
26 whether an intervention offers good value for money. In general, an intervention was
27 considered to be cost effective if any of the following criteria applied (provided that
28 the estimate was considered plausible):

- 29 • the intervention dominated other relevant strategies (that is, it was both less costly
30 in terms of resource use and more effective compared with all the other relevant
31 alternative strategies)
- 32 • the intervention cost less than £20,000 per QALY gained compared with the next
33 best strategy
- 34 • the intervention provided important benefits at an acceptable additional cost when
35 compared with the next best strategy.

36 The committee's considerations of cost effectiveness are discussed explicitly under
37 the heading 'Cost effectiveness and resource use' in 'The committee's discussion of
38 the evidence' section of the relevant evidence reviews.

39 Details of the cost effectiveness analyses undertaken for the guideline are presented
40 in appendix I of the relevant evidence reviews.

1 Other sources of evidence

2 External experts (expert witness)

3 In addition to the sources of evidence used for this guideline described above,
4 testimony from expert witnesses was also used as a basis for recommendations,
5 namely as a means of addressing key themes in the scope that were not adequately
6 covered by recommendations from existing NICE guidelines or statements generated
7 for the formal consensus process. Expert witnesses are not members of the
8 committee, they do not have voting rights and they are not involved in the final
9 decisions or influence the wording of recommendations.

10 An equality impact assessment that was undertaken for the guideline highlighted that
11 people from Black, Asian and Minority Ethnic communities can face disparity in
12 access and discrimination in health and social care services, and are
13 underrepresented in those accessing advocacy services. However, there was a
14 paucity of existing NICE recommendations addressing this. The formal consensus
15 process did result in some statements relating to culturally appropriate advocacy but
16 in discussions with the committee it was agreed that there was not enough detail
17 from the statements in order to fully address this issue. Therefore, the committee
18 agreed to invite expert witnesses to provide testimony about specific approaches for
19 overcoming barriers to accessing advocacy services for people from Black, Asian
20 and Minority Ethnic communities, as well as addressing stigma, discrimination and
21 unconscious bias in advocacy services. The expert witnesses presented testimony
22 directly to the committee, as opposed to using this as an additional source of material
23 for generating statements to be used in the formal consensus process, due to the
24 time required for the formal consensus process.

25 The two expert witnesses submitted a written testimony in response to a brief drafted
26 by the NGA technical team, and then presented this testimony to the committee and
27 answered questions. The committee used the testimony to refine and expand
28 recommendations about culturally appropriate advocacy and cultural competence
29 that were made following the formal consensus exercise (see 'Developing
30 recommendations' below). The written testimony is provided in appendix H of
31 evidence review F and how this impacted recommendations is documented under
32 the heading 'The committee's discussion of the evidence' in relevant evidence
33 reviews.

34 Developing recommendations

35 For all recommendations, the committee considered the balance between potential
36 benefits and harms and the economic costs or implications compared with the
37 economic benefits, as well as current practice, person's preferences and equality
38 issues, based on the statements, recommendations from existing NICE guidelines,
39 and their expert knowledge and experience.

40 The main considerations specific to each recommendation are outlined under the
41 heading 'The committee's discussion of the evidence' within each evidence review.

42 For further details refer to Developing NICE guidelines: the manual.

1 Additional information relevant to developing recommendations based on the
2 different approaches used for this guideline are described in the sections below.

3 **Adopting and adapting existing NICE recommendations**

4 Existing recommendations for each area of the scope were presented to the
5 guideline committee along with information about which guideline the
6 recommendation came from and a brief summary of the evidence underpinning the
7 recommendation. Where existing recommendations addressed a number of concepts
8 within one recommendation, only those relevant to advocacy were presented to the
9 committee. Moreover, there were a number of existing recommendations under the
10 key themes of 'Who else would benefit from advocacy and how do we identify them?'
11 and 'Information about effective advocacy and signposting to services' that covered
12 the same action for different populations and were all based on informal consensus.
13 These recommendations were combined prior to presentation to the guideline
14 committee to avoid repetition and streamline discussions.

15 For each recommendation (or group of recommendations in the event of
16 recommendations being combined), the committee discussed whether the
17 recommendation should be adopted (included in the current guideline exactly as it
18 appears in the original guideline), adapted (modified for use in the current guideline),
19 or discarded (not used in the current guideline but remain as it appears in the original
20 guideline). Many of the existing NICE guidelines have a narrower focus in terms of
21 population than the current guideline. Therefore, as part of this process the
22 committee considered whether existing recommendations could be generalised to
23 the broader context of this guideline, taking into account the population and
24 underpinning evidence for the recommendation in the original guideline. Adaptations
25 to recommendations included broadening the population or context of the original
26 recommendation and editorial changes or changes to presentation to collate related
27 recommendations and avoid repetition. Reasons for discarding recommendations
28 included avoiding repetition, the need for the recommendation being superseded by
29 other recommendations made in the current guideline, and the population or context
30 being too specific. The action taken for each identified relevant existing NICE
31 recommendation is presented in appendix F within each evidence review, alongside
32 justification for the action, the underpinning evidence as documented in the original
33 NICE guideline, and the final recommendation agreed for this guideline. Where
34 recommendations have been adapted, additional information on how and why the
35 recommendation was adapted is documented under the heading 'The committee's
36 discussion of the evidence' within each evidence review.

37 **New guideline recommendations based on formal consensus**

38 The statements carried forward to the committee discussion did not form
39 recommendations themselves; rather they were used as the basis to inform
40 recommendations. The statements were considered by the committee in a similar
41 way to how evidence from traditional evidence reviews would be considered and 'The
42 committee's discussion of the evidence' section of each evidence reviews documents
43 how the committee supplemented the statements with their expertise and experience
44 to arrive at the recommendations.

45 Not all of the statements that were carried forward to committee discussion were
46 used to inform recommendations. As with the recommendations from existing NICE

1 guidelines, some statements were not used to inform a recommendation as the
2 concept covered by the statement was already addressed by another
3 recommendation. Moreover, some statements did not provide enough information to
4 inform a specific action that would address the issue covered by the statement or the
5 action required was outside the remit of NICE guidelines. The NGA technical team
6 reviewed the statements to highlight those that may fall into these categories prior to
7 presenting the statements for each key area of the scope to the guideline committee.
8 However, the committee were given the opportunity to review and discuss these
9 statements alongside the remaining statements for each area. If any statements were
10 not used to inform recommendations following discussion with the guideline
11 committee, this was also documented under the heading 'The committee's
12 discussion of the evidence' within each evidence review.

13 **New guideline recommendations based on informal consensus**

14 The committee identified a number of gaps in relation to key themes in the scope that
15 they agreed were not adequately covered by recommendations made following the
16 above processes. In these instances the committee drafted recommendations based
17 on their expertise and experience alone. Such recommendations still required
18 consideration of the factors outlined above (potential benefits, harms and costs) but
19 did not follow a formal process for reaching consensus on the recommendation. As
20 with the other recommendations, the main considerations specific to each
21 recommendation are outlined under the heading 'The committee's discussion of the
22 evidence' within each evidence review.

23 **Research recommendations**

24 The committee considered making recommendations for future research in areas
25 where there were a lack of existing NICE recommendations or statements generated
26 for the formal consensus process or if statements indicated a need for further
27 research. For further details refer to Developing NICE guidelines: the manual and
28 NICE's Research recommendations process and methods guide.

29 **Validation process**

30 This guideline was subject to a 6-week public consultation and feedback process. All
31 comments received from registered stakeholders were responded to in writing and
32 posted on the NICE website at publication. For further details refer to Developing
33 NICE guidelines: the manual.

34 **Funding**

35 The NGA was commissioned by NICE to develop this guideline.

1 **References**

2 **Brouwers 2010**

3 Brouwers, M., Kho, M. E., Browman, G. P., Burgers, J. S., Cluzeau, F., Feder, G.,
4 Fevers, B., Graham, I. D., Grimshaw, J., Hanna, S., Littlejohns, P., Makarski, J.,
5 Zitzelsberger, L., for the AGREE Next Steps Consortium. (2010) AGREE II:
6 Advancing guideline development, reporting and evaluation in healthcare. The
7 Canadian Medical Association Journal. doi: 10.1503/cmaj.090449

8 **Critical Appraisal Skills Programme 2018**

9 Critical Appraisal Skills Programme 2018. CASP Qualitative Checklist. [online]
10 Available from [https://casp-uk.net/wp-content/uploads/2018/01/CASP-Qualitative-](https://casp-uk.net/wp-content/uploads/2018/01/CASP-Qualitative-Checklist-2018.pdf)
11 [Checklist-2018.pdf](https://casp-uk.net/wp-content/uploads/2018/01/CASP-Qualitative-Checklist-2018.pdf) (accessed 4 March 2022)

12 **Murphy 1998**

13 Murphy M. K., Black N. A., Lamping D., McKee C., Sanderson C., Askham J., et al.
14 (1998) Consensus development methods, and their use in clinical guideline
15 development. *Health Technology Assessment*, 2

16 **NICE 2018**

17 National Institute for Health and Care Excellence (NICE) (2014) NICE Policy on
18 conflicts of interest (updated 2017). Available from
19 [https://www.nice.org.uk/Media/Default/Get-](https://www.nice.org.uk/Media/Default/Get-involved/Fellows%20and%20scholars%20unsecure/Conflicts-of-interest-policy.pdf)
20 [involved/Fellows%20and%20scholars%20unsecure/Conflicts-of-interest-policy.pdf](https://www.nice.org.uk/Media/Default/Get-involved/Fellows%20and%20scholars%20unsecure/Conflicts-of-interest-policy.pdf)
21 (accessed 4 March 2022)

22 **Whiting 2016**

23 Whiting, P., Savović, J., Higgins, J. P. T., Caldwell, D. M., Reeves, B. C., Shea, B.,
24 Davies, P., Kleijnen, J., Churchill, R., the ROBIS group. (2016). *Journal of Clinical*
25 *Epidemiology*, 68, 225-234